CEACAM5 and squamous cell carcinoma: Then, the remaining six significant factors (comorbidities, presence of squamous cell carcinoma (SCC), PD-L1 expression of pre-NCIO, pembrolizumab/nab-paclitaxel–based regimens, tumor size of post-NCIO, and tumor regression rate) of pCR and seven significant factors (presence of SCC, PD-L1 expression of pre-NCIO, CEA of pre-NCIO, HDL-C of pre-NCIO, pembrolizumab/nab-paclitaxel–based regimens, tumor size of post-NCIO, tumor regression rate) of MPR were chosen for the multivariate logistic regression model.